Bionomics is an Australian biotech focused on CNS and oncology. BNC375 (preclinical) is partnered with Merck for Alzheimer’s disease; BNC210 (Ph I) is in development for anxiety. A partnership is sought for cancer drug BNC105 (Ph II).
More Bionomics content >Investment summary
The fiscal year 2018, which ended in June, was a major transition for Bionomics as it realigned itself to focus on disorders of the central nervous system. This strategy hinges on the company’s lead asset BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which has a potentially novel anxiolytic mechanism of action. The drug is in Phase IIb for post-traumatic stress disorder (PTSD) (with a readout expected in this quarter) and Phase IIa for agitation in the elderly.
Y/E Jun |
Revenue (A$m) |
EBITDA (A$m) |
PBT (A$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 18.6 | (3.2) | (4.4) | (1.00) | N/A | N/A |
| 2018A | 4.0 | (22.5) | (24.4) | (4.84) | N/A | N/A |
| 2019E | 17.9 | (17.7) | (19.3) | (3.65) | N/A | N/A |
| 2020E | 4.3 | (28.4) | (32.5) | (5.86) | N/A | N/A |
Industry outlook
There are currently no approved medications for agitation in the elderly. BNC210 hopes to surmount this with its novel anxiolytic mechanism.
Last updated on 27/03/2019Content on Bionomics
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (A$m) | 19 |
| Forecast gearing ratio (%) | 697 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Christopher Fullerton | Chairman |
| Dr Errol De Souza | Chairman |
| Graeme Kaufman | Chairman |
| Deborah Rathjen | CEO |
| Melanie Young | CFO |
| Steven Lydeamore | CFO |
| Deborah Rathjen | CEO & Managing Director |